Home Page Potential Lawsuit Invokana Linked with Cardiovascular Injuries and Kidney Failure
Invokana Linked with Cardiovascular Injuries and Kidney Failure
Were you looking for FDA Warns of Ketoacidosis Linked to SGLT2 inhibitors Canagliflozin, Dapagliflozin, and Empagliflozin or SGLT2 Inhibitor Forxiga Safety Review Launched lawsuits?
By Heidi Turner
Invokana lawsuits have been filed against Janssen Pharmaceuticals alleging Invokana side effects include an increased risk of kidney problems and cardiovascular problems. Additionally, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have issued warnings about kidney problems and diabetic ketoacidosis—both of which are serious conditions—potentially linked to Invokana use.
En Español [INVOKANA]
Invokana (canagliflozin), is a type 2 diabetes medication and is in a class of drugs known as SGLT2 inhibitors. It works by causing the kidneys to remove sugar from the blood via urine and was first approved by the US Food and Drug Administration (FDA) in 2013. Some diabetes patients may be prescribed Invokamet, which is a diabetes medication combining Invokana with metformin hydrochloride (Glucophage).
Other drugs in the SGLT2 class include dapagliflozin (Forxiga) and empagliflozin (Jardiance), Xigduo XR (dapagliflozin and metformin extended-release) and Glyxambi (empagliflozin and linagliptin).
Invokana lawsuits have now been filed against Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, alleging patients suffered serious side effects as a result of the use of Invokana. One such lawsuit (Maddox v. Janssen Pharmaceuticals, et al, case number; 2:16-cv-01189) alleges patients who were prescribed Invokana "have suffered and may continue to suffer severe and permanent personal injuries, including diabetic ketoacidosis, stroke, heart attack, and severe kidney damage."
Maddox's lawsuit alleges the defendants knew or should have known about the risks but failed to adequately warn patients, putting them at risk of diabetic ketoacidosis, cardiovascular problems and kidney damage. Specifically, Maddox argues he developed ketoacidosis and kidney damage less than a year after starting Invokana treatment.
In May 2015, the FDA warned that Invokana was linked to ketoacidosis, a serious condition in which the body produces high levels of ketones. Patients were warned to watch for signs of ketoacidosis, including difficulty breathing, nausea, vomiting, abdominal pain, confusion and unusual fatigue or sleepiness and seek medical attention if any signs of ketoacidosis occur.
According to the Mayo Clinic, DKA symptoms may also include excessive thirst, frequent urination and even fruity-scented breath. Diabetes patients can typically recognize signs of diabetic ketoacidosis via home blood and urine tests that indicate high blood sugar levels (hyperglycemia) and/or high ketone levels.
The FDA's warning was based on its Adverse Event Reporting System (FAERS), which contained 20 cases of acidosis, ketoacidosis or ketosis in patients treated with SGLT2 inhibitors between March 2013 and June 2014. FDA notes that more Invokana FAERS reports have been received since June 2014. All patients reportedly required hospitalization.
Diabetic ketoacidosis is a serious condition that occurs when insulin levels are too low resulting in excessively high blood sugar levels. The body then burns fat for fuel, resulting in ketones building up, which upsets the blood's chemical balance. A person experiencing DKA may require emergency care and hospitalization to treat the ketoacidosis.
In March 2015, the FDA requested an update to Invokana's label to warn about the risk of genital mycotic infections (yeast infections) in both males and females. A study presented at the American Diabetes Association (ADA) 2013 Scientific Sessions suggested 10 percent of women taking Invokana experienced a yeast infection compared with three percent of women who took a placebo.
Invokana Adverse Reactions
Invokana has reportedly been linked to an increased risk of kidney problems. In 2015, the Institute for Safe Medication Practices warned in its quarterly report that it had identified 457 serious adverse event reports, including kidney failure or impairment, dehydration and fluid imbalances, kidney stones, urinary tract infections and abnormal weight loss.
On February 12, 2016, the European Medicines Agency (EMA) issued recommendations concerning SGLT2 Inhibitors. The agency warned that patients taking such medications should contact healthcare professionals immediately and treatment should be stopped if diabetic ketoacidosis is confirmed.
In addition to Invokana and Invokamet, the FDA has also issued a warning about SGLT2 inhibitors potentially leading to DKA. The FDA is investigating type 2 diabetes medications including dapagliflozin (Forxiga) and empagliflozin (Jardiance). Additionally, two other SGLT2 inhibitors, Xigduo XR (dapagliflozin and metformin extended-release) and Glyxambi (empagliflozin and linagliptin) are also being investigated.
SGLT2 Inhibitor FDA Warning
Invokana LawsuitsAttorneys are investigating possible Invokana lawsuits. Patients who have suffered adverse events after using Invokana—or people whose loved ones died after suffering an adverse event—may be eligible to file a lawsuit. If you or a loved one has suffered damages or injuries due to Invokana, please click the link below and your complaint will be sent to a Drug and Medical Device lawyer who will evaluate your claim at no cost or obligation.
Last updated on
INVOKANA LEGAL ARTICLES AND INTERVIEWS
FDA Black Box Warning Adds Fuel to Invokana Lawsuits
Philadelphia, PA Final results from two independent clinical trials indicate the amputation risk for users of the Type 2 Diabetes drug Canagliflozin, marketed as Invokana, Invokamet, Invokamet XR, are much greater than previously understood [READ MORE]
Invokana Adverse Events Subject to Much Scrutiny
Boston, MA: A new study recently published in the New England Journal of Medicine (06/08/17) with regard to the potential for diabetic ketoacidosis (DKA) shows that type 2 diabetes patients on sodium-glucose cotransporter 2 (SGLT2) inhibitor drugs appear to have double the risk for DKA when compared with patients using dipeptidyl peptidase-4 (DPP-4) inhibitors. Invokana is a member of the SGLT2 class, and ample concern has been expressed over Invokana linked with cardiovascular injuries and kidney failure [READ MORE]
Invokana to Get Black-Box Warning over Amputation Risk
Washington, DC: An issue that looms even larger than that of Invokana linked with cardiovascular injuries and kidney failure is the potential for amputation associated with the diabetes drug. The issue first surfaced a year ago when the US Food and Drug Administration (FDA) issued an alert after studying the results of two clinical trials, warning that users of Invokana and Invokamet were twice as likely to require amputations of appendages, or limbs [READ MORE]
MORE INVOKANA LEGAL NEWS
READ MORE [ Diabetes Drugs Settlements and Legal News ]
READ MORE [ Defective Products Settlements and Legal News ]
READ MORE [ Drugs/Medical Settlements and Legal News ]
READ MORE [ Personal Injury Settlements and Legal News ]
I HAVE BEEN TAKING INVOKANA FOR ABOUT FOUR MONTHS,THE FIRST MONTH WAS GREAT BLOOD SUGARS REALY LOW. THEN IT STOPED WORKING AT ALL, NOW I CAN'T GET THEM DOWN AT ALL ,I TAKE A LOT OF INSULAN AND I JUST CHEKED ABOUT AN HOUR AGO AND WAS 456, I CAN'T IMAGINE WATS GOING ON.
ADD YOUR COMMENT ON THIS ISSUE